Akesis Pharmaceuticals Completes Phase IIa Trial Of AKP-020 For Type 2 Diabetes

Akesis Pharmaceuticals, Inc. (OTCBB:AKES), an emerging diabetes drug-development company, announced that it has completed the recruitment and dosing phases in its placebo-controlled Phase IIa trial designed to test the safety and efficacy of AKP-020, a novel vanadium compound, in patients with Type 2 diabetes. ...

Write comment to this article:

Subject:

Name:

email or site:

Code: